Skip to main content
. Author manuscript; available in PMC: 2023 Sep 1.
Published in final edited form as: J Control Release. 2022 Jul 14;349:413–424. doi: 10.1016/j.jconrel.2022.07.008

Fig. 7. Localization of PLN-formulated ICLs in brain-invading cells 48h post-injection.

Fig. 7.

A-B) Representative high-magnification fields of diffuse midline glioma GEMM with engineered human IL13Rα2 receptor 48h after injection of PLN-formulated DiD. Immunostaining for IL13Rα2 was used to identify tumor cells. In addition, sequential H&E staining is shown to confirm the tumor edge. There was colocalization of DiD with the invasive margin and some of the breakaway cells (yellow arrows).